Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) Assets Average (2024 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Assets Average for 2 consecutive years, with $777.9 million as the latest value for Q4 2025.

  • Quarterly Assets Average rose 19.32% to $777.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $777.9 million through Dec 2025, up 19.32% year-over-year, with the annual reading at $817.0 million for FY2025, 34.84% up from the prior year.
  • Assets Average hit $777.9 million in Q4 2025 for NewAmsterdam Pharma, down from $800.8 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $841.5 million in Q1 2025 to a low of $417.8 million in Q1 2024.